Introduction

Capcitab 150 mg (Capecitabine) Tablet is an oral chemotherapeutic agent designed to treat colorectal cancer, breast cancer, and gastric cancer. Manufactured by Eskayef Pharmaceuticals Ltd., a WHO-GMP-certified leader in oncology therapeutics, and supplied globally by Onco Solution, this lower-dose formulation offers precise dosing flexibility for tailored cancer treatment. As a prodrug of 5-fluorouracil (5-FU), Capcitab 150 mg (Capecitabine) Tablet is enzymatically converted into its active form within the body, disrupting cancer cell proliferation through dual mechanisms of DNA and RNA interference.

Key Benefits & Mechanism of Action

Capcitab 150 mg (Capecitabine) Tablet mimics natural cellular components to sabotage cancer cell growth via two critical pathways:

1. Conversion to 5-FU: Enzymes in tumor tissues and the liver metabolize capecitabine into 5-fluorouracil (5-FU), a potent antimetabolite.
2. DNA Synthesis Inhibition:
   • 5-FU is converted to 5-fluoro-2’-deoxyuridine monophosphate (FdUMP), which binds to thymidylate synthase (TS) along with folate cofactors (N⁵-¹⁰-methylene tetrahydrofolate).
   • This forms a stable ternary complex, blocking the conversion of deoxyuridylate to thymidylate—a critical precursor for DNA replication.
3. RNA Disruption:
   • 5-FU is metabolized into 5-fluorouridine triphosphate (FUTP), which is mistakenly incorporated into RNA strands during synthesis.
   • This disrupts RNA processing and protein synthesis, leading to cancer cell apoptosis.

Clinical Applications & Indications

Capcitab 150 mg (Capecitabine) Tablet is approved for:

• Colorectal Cancer: Adjuvant therapy for stage III colon cancer and first-line treatment for metastatic disease (often combined with oxaliplatin).
• Breast Cancer: Monotherapy for metastatic HER2-negative breast cancer or combination therapy with docetaxel.
• Gastric Cancer: Post-surgical adjuvant treatment to reduce recurrence risk.

Why Choose Capcitab 150 mg (Capecitabine) Tablet?

• Precision Dosing: The 150 mg strength allows tailored regimens for patients requiring dose adjustments due to toxicity or comorbidities.
• Targeted Activation: Higher 5-FU concentration in tumor tissues minimizes systemic side effects.
• Oral Convenience: Eliminates the need for IV infusions, enabling home-based care.
• Proven Efficacy: Supported by phase III trials like X-ACT and RESPECT, demonstrating improved survival outcomes.
• Global Quality Assurance: Produced under WHO-GMP standards by Eskayef Pharmaceuticals Ltd.

Manufacturer Credibility

Eskayef Pharmaceuticals Ltd., part of Bangladesh’s Transcom Group, has been a pioneer in oncology innovation since 1990. Their WHO-GMP-certified facilities ensure Capcitab 150 mg (Capecitabine) Tablet meets stringent global safety and efficacy benchmarks. With a legacy of delivering affordable, high-quality therapies, Eskayef serves patients across Asia, Africa, and Europe. Learn more at www.skfbd.com.

Supplier Profile: Onco Solution

Onco Solution is a trusted global supplier dedicated to equitable access to life-saving cancer treatments like Capcitab 150 mg (Capecitabine) Tablet. Their services include:

• Flexible Procurement: Competitive pricing for clinics, hospitals, and individual patients.
• Global Supply Network: Reliable delivery to 50+ countries, including low-resource regions.
• Clinical Guidance: Access to dosing protocols and expert consultations via www.oncosolution.com.

Driven by innovation and compassion, Onco Solution bridges gaps in cancer care through affordable pricing and patient education.

Technical Specifications

• Active Ingredient: Capecitabine 150 mg
• Dosage Form: Film-coated oral tablet
• Storage: Store below 25°C in a dry, light-resistant container.
• Administration: Twice daily with food (e.g., 14-day cycles followed by 7-day rest periods).

Patient-Centric Advantages

• Dosing Flexibility: Adjustable regimens to manage side effects like hand-foot syndrome or diarrhea.
• Reduced Hospital Dependency: Supports outpatient care, improving quality of life.
• Cost-Effective: Lower financial burden compared to IV chemotherapy.

Clinical Efficacy & Safety

• X-ACT Trial: Showed 64% reduction in relapse risk for stage III colon cancer vs. 5-FU/leucovorin.
• RESPECT Trial: Demonstrated 30% overall response rate in metastatic breast cancer.
• Common Side Effects: Hand-foot syndrome (50%), diarrhea (30%), fatigue (25%).
• Severe Reactions: Rare myelosuppression or cardiotoxicity (monitor cardiac function).

Global Accessibility & Partnerships

Through collaboration with Eskayef Pharmaceuticals Ltd., Onco Solution ensures Capcitab 150 mg (Capecitabine) Tablet is accessible in underserved regions, prioritizing:

• Affordability: Tiered pricing for developing nations.
• Quality Compliance: Adherence to WHO-GMP and ISO standards.
• Education: Training programs for healthcare providers on toxicity management.

Ordering Information

Healthcare providers and patients can procure Capcitab 150 mg (Capecitabine) Tablet through Onco Solution’s streamlined platform:

• Bulk Orders: Discounted rates for hospitals and oncology centers.
• Dose Guidance: Protocols for managing dose-limiting toxicities.
• Global Network: Connect with specialists via www.oncosolution.com.

Conclusion

Capcitab 150 mg (Capecitabine) Tablet offers a patient-centric, precision approach to oral chemotherapy for colorectal, breast, and gastric cancers. With Eskayef Pharmaceuticals Ltd. ensuring uncompromised quality and Onco Solution enabling global access, this therapy empowers patients and clinicians to combat cancer effectively. For orders or clinical support, contact Onco Solution today.